Peripheral Arterial Disease
Conditions
Keywords
Peripheral arterial disease, Platelet lysate
Brief summary
Allogenic platelet lysate will be injected in the gastrocnemius of patients with peripheral arterial disease (PAD)
Detailed description
Allogenic platelet rich plasma (PRP) will be collected from blood group AB donors. This plasma will be tested for the presence of any chronic infectious blood borne disease. Platelet lysate will be then prepared from the tested PRP to be intramuscularly injected in patients with PAD
Interventions
BIOLOGICALPlatelet lysate
Intramuscular injection of platelet lysate
BIOLOGICALPlacebo
intramuscular injection of normal saline
Sponsors
Sophia Al-Adwan
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
50 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Competent and willing to give informed consent, and to be available for all baseline treatment and follow up examinations required by the protocol. * Gender: Male or female. * Age group \> 50 years. * Established Critical limb ischemia (CLI), clinically and hemodynamically confirmed as per Rutherford 3, 4 and 5 with angiographic evidence of significant infra-inguinal arterial occlusive disease. * History of intermittent claudication for \> eight weeks. * Limited exercise due to moderate to severe claudication. * Resting ABI \< 0.6, toe pressure ≤ 60 mm Hg, Toe Brachial index (TBI) \<0.6, or TcPO2 ≤ 60 mmHg in the foot. * Not eligible for surgical or radiological revascularization, and doesn't respond to best standard care delivered as confirmed by a vascular surgeon and/or physician. * Fairly controlled diabetes (Hemoglobin A1c \<10%). * Normal liver enzymes, serum creatinine \< 1.4 * Normal platelet count. * On regular medication for hypertension if any. * No evidence of malignancy * Body mass index \<30.
Exclusion criteria
* Women with child bearing potential, pregnant and lactating women. * Rheumatoid Arthritis. * History of neoplasm or malignancy in the past 10 years. * Reported unstable cardiovascular disease, heart failure or symptomatic postural hypotension within 6 months before screening. * Leg edema * Inflammatory or progressive fibrotic disorder * Renal insufficiency or failure * History of infectious disorder (Human immunodeficiency virus (HIV) and/or hepatitis viruses). * Chronic inflammatory disease * History of stroke or myocardial infarction (\< 3 months). * Bleeding or clotting disorder, use of oral anticoagulant therapy (heparin, warfarin).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] | 6 months | Frequency and nature of adverse events occurring during a 6-month period following platelet lysate injection(s). This will be assessed by physical examination combined with a report with chemistry blood tests. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Evaluation of the preliminary efficacy of the platelet lysate injection on patients' ABI | 12 months | Positive changes in patients' Ankle brachial index (ABI) |
| Evaluation of the preliminary efficacy of the platelet lysate injection on patients' Toe pressure | 12 months | Positive changes in patients' Toe pressure (mm Hg) |
| Evaluation of the preliminary efficacy of the platelet lysate injection on patients' TcPO2 | 12 months | Positive changes in patients' Transcutaneous oxygen pressure (TcPO2) |
Countries
Jordan
Contacts
Primary ContactSofia Adwan, Msc
Outcome results
None listed